Human parvoviruses B19, PARV4 and bocavirus in pediatric patients with allogeneic hematopoietic SCT

Area of Science:

• Virology
• Immunology
• Pediatrics

Background:

• Parvovirus B19 (B19V) can cause severe illness post-hematopoietic stem cell transplant (HSCT).
• The impact of human bocavirus 1 (HBoV1) and parvovirus 4 (PARV4) in immunocompromised individuals remains unclear.
• Understanding parvovirus epidemiology in HSCT recipients is crucial for managing immunocompromised patients.

Purpose of the Study:

• To investigate the occurrence and clinical spectrum of B19V, PARV4, and HBoV1 infections in pediatric HSCT recipients.
• To determine the frequency and viral load of parvovirus DNAemias before and after HSCT.
• To assess the clinical manifestations associated with these parvovirus infections post-transplant.

Main Methods:

• Longitudinal molecular surveillance of 53 pediatric allogeneic HSCT recipients.
• Quantitative real-time PCR assays for B19V, PARV4, and HBoV1 DNA in serum samples.
• Pre- and post-HSCT sample collection for DNAemia analysis.

Main Results:

• B19V DNA was detected in 30% of patients, with varying viral loads pre- and post-HSCT.
• No clinical manifestations were correlated with the presence of B19V viremia.
• PARV4 and HBoV1 DNA were not detected in any of the investigated serum samples.

Conclusions:

• B19V viremia is frequent in pediatric allogeneic HSCT recipients but appears to have no significant clinical impact.
• PARV4 and HBoV1 infections were not observed in this cohort of immunocompromised patients.
• Further research may be needed to understand the long-term implications of B19V viremia in HSCT survivors.